Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi-Reference-Cited by-同舟云学术

Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi

Published:2014-03-07 Issue:1 Volume:166 Page:140-142
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Anastasia Antonella¹,Carlo-Stella Carmelo¹²,Corradini Paolo³⁴,Salvi Flavia⁵,Rusconi Chiara⁶,Pulsoni Alessandro⁷,Hohaus Stefan⁸,Pregno Patrizia⁹,Viviani Simonetta¹⁰,Brusamolino Ercole¹¹,Luminari Stefano¹²,Giordano Laura¹,Santoro Armando¹

Affiliation:

1. Department of Oncology and Haematology; Humanitas Cancer Centre; Humanitas Clinical and Research Centre; Rozzano (MI) Italy

2. Department of Medical Biotechnology and Translational Medicine; University of Milano; Milano Italy

3. Department of Haematology and Bone Marrow Transplantation; Fondazione IRCCS Istituto Nazionale Tumori; Milano Italy

4. Chair of Haematology; University of Milano; Milano Italy

5. Division of Haematology; AO SS Antonio e Biagio e C. Arrigo; Alessandria Italy

6. Division of Haematology; Niguarda Ca' Granda Hospital; Milano Italy

7. Department of Cellular Biotechnologies and Haematology; “Sapienza” University; Roma Italy

8. Institute of Haematology; Università Cattolica S. Cuore; Roma Italy

9. Haematology; A.O. Città della Salute e della Scienza; Torino Italy

10. Department of Medical Oncology; Fondazione IRCCS Istituto Nazionale Tumori; Milano Italy

11. Division of Haematology; Policlinico S Matteo; Pavia Italy

12. Department of Diagnostic Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12821/fullpdf

Reference4 articles.

1. Revised response criteria for malignant lymphoma;Cheson;Journal of Clinical Oncology,2007

2. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma;Corazzelli;British Journal of Haematology,2013

3. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation;Gopal;Blood,2012

4. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma;Moskowitz;Journal of Clinical Oncology,2013

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful restoration of checkpoint inhibitors efficacy after allogeneic hematopoietic cell transplant for classic Hodgkin lymphoma patients;Seminars in Oncology;2023-06

2. Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review;Cancers;2023-02-28

3. Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma;Blood Advances;2021-12-17

4. Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience;Clinical Lymphoma Myeloma and Leukemia;2021-09

5. Successful Use of Nivolumab in a Patient with Head and Neck Cancer After Allogeneic Bone Marrow Transplantation;OncoTargets and Therapy;2021-02